Veru Q3 net loss narrows to $0.50/sh; enobosarm Phase 2b data show lean mass preservation

VERU INC.

Net loss from continuing ops $7.3M ($0.50/sh) vs $10.3M ($0.71/sh) in Q3 2024.
R&D expense $3.0M, down from $4.8M; SG&A $5.0M, down from $5.8M.
Cash $15.0M at June 30, 2025 vs $24.9M at Sep 30, 2024; burn funds clinical programs.
Phase 2b QUALITY: enobosarm 3mg + semaglutide preserved 100% lean mass (p<0.001) and increased fat loss 12% vs semaglutide alone.
Maintenance Extension: enobosarm 3mg monotherapy reduced weight regain by 46% after semaglutide discontinuation.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.